Status: Recruiting
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy
This study is a phase 3 clinical trial, aiming to evaluate the efficacy and safety of HRS-9531 injection in obese subjects with obstructive sleep apnea (OSA) who are on positive airway pressure ventilation (PAP) therapy.
Participants needed: 140
Trial details
Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Fujian Shengdi Pharmaceutical Co., Ltd.Updated: Jan 26, 2026Locations: 1
Eligibility criteria
Aged 18 -75 (inclusive), male or female Sex [+5]
Endocrine disorders significantly affecting weight (e.g., Cushing's syndrome, hy... [+9]